drugset
Drugs / rVSV boost
last change Dec 2023 re-read 3 minutes ago

rVSV boost

Developed for
Ebola hemorrhagic fever
Investigated by
European and Developing Countries Clinical Trials Partnership (EDCTP) · French National Institute of Health and Medical Research · London School of Hygiene and Tropical Medicine · National Institute of Allergy and Infectious Diseases (NIAID) · Partnership for Research on Ebola Virus in Liberia (PREVAIL)

Trials 1

today NCT02876328 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02876328 Mar 2017 → Dec 2019 Ebola hemorrhagic fever National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rVSV boost ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876328 ↗